Long-term outcome of patients with mutiple myeloma-related advanced renal failure following auto-SCT

Bone Marrow Transplantation

Volumn 48, Issue 12, 2013, Pages 1543-1547

  Glavey, S V ^a   Gertz, M A ^b   Dispenzieri, A ^b   Kumar, S ^b   Buadi, F ^b   Lacy, M ^b   Hayman, S R ^b   Dingli, D ^b   Mccurdy, A ^b   Hogan, W J ^b   Gastineau, D A ^b   Leung, N ^b  

^a UNIVERSITY HOSPITAL GALWAY   (Ireland)

^b MAYO CLINIC   (United States)

Author keywords

auto SCT; dialysis; renal

Indexed keywords

ANTINEOPLASTIC AGENT; CREATININE; MELPHALAN; NONSTEROID ANTIINFLAMMATORY AGENT; PLATINUM COMPLEX;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTEREMIA; CLINICAL ARTICLE; COHORT ANALYSIS; CREATININE BLOOD LEVEL; ENGRAFTMENT SYNDROME; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; SEPSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; YOUNG ADULT;

ADULT; AGED; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84889571313     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2013.109     Document Type: Article

References (18)

1. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar S, Leung N et al. Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplant 2007; 39: 605-611 (Pubitemid 46729052)
2. San Miguel JF, Lahuerta JJ, Garcia-Sanz R, Alegre A, Blade J, Martinez R et al. Are myeloma patients with renal failure candidates for autologous stem cell transplantatioñ Hematol J 2000; 1: 28-36
3. Blade J, Fernandez-Llama P, Bosch F, Montoliu J, Lens XM, Montoto S et al. Renal failure in multiple myeloma: Presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998; 158: 1889-1893 (Pubitemid 28440861)
4. Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J. Renal function in newly diagnosed multiple myeloma-A demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur J Haematol 1994; 53: 207-212 (Pubitemid 24347964)
5. Matsue K, Fujiwara H, Iwama K, Kimura S, Yamakura M, Takeuchi M. Reversal of dialysis-dependent renal failure in patients with advanced multiple myeloma: Single institutional experiences over 8 years. Ann Hematol 2010; 89: 291-297
6. Dimopoulos MA, Richardson PG, Schlag R, Khuageva NK, Shpilberg O, Kastritis E et al. VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: Cohort analysis of the phase III VISTA study. J Clin Oncol 2009; 27: 6086-6093
7. Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: Reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 2000; 65: 175-181
8. Torra R, Blade J, Cases A, Lopez-Pedret J, Montserrat E, Rozman C et al. Patients with multiple myeloma requiring long-Term dialysis: Presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol 1995; 91: 854-859
9. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. New Engl J Med 1996; 335: 91-97 (Pubitemid 26240110)
10. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. New Engl J Med 2003; 348: 1875-1883 (Pubitemid 36532313)
11. Parikh GC, Amjad AI, Saliba RM, Kazmi SM, Khan ZU, Lahoti A et al. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant 2009; 15: 812-816
12. Knudsen LM, Nielsen B, Gimsing P, Geisler C. Autologous stem cell transplantation in multiple myeloma: Outcome in patients with renal failure. Eur J Haematol 2005; 75: 27-33 (Pubitemid 40873958)
13. Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 114: 822-829 (Pubitemid 32953738)
14. Lee CK, Zangari M, Barlogie B, Fassas A, van Rhee F, Thertulien R et al. Dialysisdependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant 2004; 33: 823-828 (Pubitemid 38519243)
15. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461
16. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 21-33 (Pubitemid 36033957)
17. Ludwig H, Adam Z, Hajek R, Greil R, Tothova E, Keil F et al. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin- dexamethasone in multiple myeloma: Results of a phase II study. J Clin Oncol 2010; 28: 4635-4641
18. Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: Results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol 2012; 30: 2946-2955